Floatz logo

Irinotecan

Intrahepatic Cholangiocarcinoma (Icc)

Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma (Icc) cohort.

Asset / SponsorPhaseRating
Durvalumab
West China Hospital
Phase 2BB
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai 6th People's Hospital
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2B
Ipilimumab
TriSalus Life Sciences, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →